雅虎香港 搜尋

搜尋結果

  1. 2024年3月29日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) and muscle relaxant ®

  2. 剤形名. メリスロン錠6mg. メリスロン錠6mgの添付文書、インタビューフォームなどの情報を掲載しています。. エーザイの医療関係者向け情報サイトです。. 医療用医薬品を適正にご使用いただくための情報を提供しています。.

  3. Brand name. Merislon Tablets 6mg. Eisai Co., Ltd. Word. 日本語. The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy.

  4. 如何使用敏使朗(Merislon)及調較劑量? 敏使朗是一種口服藥物,可連同食物一起服用以減少腸胃不適。 成人的常用劑量為每日服用三次,每次 6-12mg。

  5. 東京都文京区小石川4-6-10. めまい・平衡障害治療剤; 総称名:メリスロン; 一般名:ベタヒスチンメシル酸塩; 販売名:メリスロン錠6mg, メリスロン錠12mg; 製造会社:エーザイ.

  6. 2022年11月7日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal ® (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) in Asia (9 countries/regions*) to a subs...

  7. MERISLON TAB 6MG. 1000粒. 成份. betahistine mesilate. 備註. 請於使用前先向醫生或藥劑師諮詢意見。. HK-48603. 網站內之產品資料只供參考,所有資料以門市為準。. MERISLON TAB 6MG, , , betahistine mesilate.

  8. 2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon® (generic name: betahistine mesilate) and muscle relaxant Myonal® (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.

  9. www.cych.org.tw › pharm › searchdrugdetail藥品詳細資訊

    治療梅尼艾氏症,劑量為一天3次,每次8~16mg。. 藥物動力學. 口服後1小時達到最高血中濃度,大部分由肝臟代謝,半衰期為3.5小時。. 可能副作用. 很少有噁心、嘔吐 及發疹等過敏症狀。. 臨床用途. 梅尼艾氏症候群所引起之眩暈、聽力障礙 。. 注意事項. 曾患有 ...

  10. 2024年3月30日 · Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon® (generic name: betahistine mesilate) and muscle relaxant Myonal® (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.

  1. 其他人也搜尋了